Philogen S.p.A. announces an update on the worldwide license agreement with Pfizer to develop Dekavil, a novel investigational therapy for the treatment of autoimmune diseases.
News & Events
Philogen announces R&D program update for Dekavil
Last News & Events
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.